Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$22.29
0.281.27%
At close: -
$22.59
0.301.35%
After Hours: 7:59 PM EDT
Comments
Loading...
IDEAYA Biosciences Analyst Ratings and Price Targets | NASDAQ:IDYA | Benzinga
IDEAYA Biosciences Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for IDEAYA Biosciences Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
JP Morgan
Stephens & Co.
RBC Capital
Wedbush
1calculated from analyst ratings
Analyst Ratings for IDEAYA Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/26/2025 | Buy Now | — | Wells Fargo | Eva Fortea Verdejo55% | → $44 | Initiates | → Overweight | Get Alert |
| 05/22/2025 | Buy Now | — | JP Morgan | Anupam Rama59% | $63 → $66 | Maintains | Overweight | Get Alert |
| 02/14/2025 | Buy Now | — | Stephens & Co. | Sudan Loganathan41% | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 01/15/2025 | Buy Now | — | RBC Capital | Gregory Renza52% | $61 → $61 | Reiterates | Outperform → Outperform | Get Alert |
| 01/13/2025 | Buy Now | — | Cantor Fitzgerald | Li Watsek43% | — | Reiterates | Overweight → Overweight | Get Alert |
| 12/17/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek43% | — | Reiterates | Overweight → Overweight | Get Alert |
| 12/17/2024 | Buy Now | — | Wedbush | Robert Driscoll44% | $52 → $52 | Reiterates | Outperform → Outperform | Get Alert |
| 11/18/2024 | Buy Now | — | Stephens & Co. | Sudan Loganathan41% | → $51 | Initiates | → Overweight | Get Alert |
| 11/05/2024 | Buy Now | — | Leerink Partners | Christopher Liu50% | $41 → $27 | Downgrade | Outperform → Market Perform | Get Alert |
| 10/29/2024 | Buy Now | — | Oppenheimer | Matthew Biegler40% | $53 → $53 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2024 | Buy Now | — | UBS | David Dai28% | → $50 | Initiates | → Buy | Get Alert |
| 09/24/2024 | Buy Now | — | Wedbush | Robert Driscoll44% | $54 → $52 | Maintains | Outperform | Get Alert |
| 09/24/2024 | Buy Now | — | RBC Capital | Gregory Renza52% | $61 → $61 | Reiterates | Outperform → Outperform | Get Alert |
| 09/10/2024 | Buy Now | — | Stifel | Benjamin Burnett44% | $63 → $68 | Maintains | Buy | Get Alert |
| 08/27/2024 | Buy Now | — | Citigroup | Yigal Nochomovitz53% | $60 → $58 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | — | JP Morgan | Anupam Rama59% | $69 → $66 | Maintains | Overweight | Get Alert |
| 08/07/2024 | Buy Now | — | RBC Capital | Gregory Renza52% | $61 → $61 | Reiterates | Outperform → Outperform | Get Alert |
| 08/07/2024 | Buy Now | — | Wedbush | Robert Driscoll44% | $54 → $54 | Reiterates | Outperform → Outperform | Get Alert |
| 08/07/2024 | Buy Now | — | Oppenheimer | Matthew Biegler40% | $60 → $53 | Maintains | Outperform | Get Alert |
| 07/12/2024 | Buy Now | — | JP Morgan | Anupam Rama59% | $65 → $69 | Maintains | Overweight | Get Alert |
| 07/11/2024 | Buy Now | — | RBC Capital | Gregory Renza52% | $53 → $61 | Maintains | Outperform | Get Alert |
| 07/09/2024 | Buy Now | — | BTIG | Justin Zelin40% | $55 → $62 | Maintains | Buy | Get Alert |
| 07/08/2024 | Buy Now | — | Stifel | Benjamin Burnett44% | $63 → $63 | Maintains | Buy | Get Alert |
| 07/08/2024 | Buy Now | — | Oppenheimer | Matthew Biegler40% | $53 → $60 | Maintains | Outperform | Get Alert |
| 07/08/2024 | Buy Now | — | Mizuho | Graig Suvannavejh50% | → $50 | Initiates | → Outperform | Get Alert |
| 06/04/2024 | Buy Now | — | Stifel | Benjamin Burnett44% | $55 → $63 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | — | Goldman Sachs | Corinne Jenkins47% | $53 → $46 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | — | Wedbush | Robert Driscoll44% | $52 → $52 | Reiterates | Outperform → Outperform | Get Alert |
| 03/21/2024 | Buy Now | — | Citigroup | Yigal Nochomovitz53% | $40 → $60 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | — | BTIG | Justin Zelin40% | → $55 | Initiates | → Buy | Get Alert |
| 02/23/2024 | Buy Now | — | JP Morgan | Anupam Rama59% | $51 → $57 | Maintains | Overweight | Get Alert |
| 02/21/2024 | Buy Now | — | RBC Capital | Gregory Renza52% | $43 → $53 | Maintains | Outperform | Get Alert |
| 01/26/2024 | Buy Now | — | Goldman Sachs | Corinne Jenkins47% | $36 → $53 | Maintains | Buy | Get Alert |
| 01/25/2024 | Buy Now | — | Goldman Sachs | Corinne Jenkins47% | $36 → $53 | Maintains | Buy | Get Alert |
| 01/10/2024 | Buy Now | — | RBC Capital | Gregory Renza52% | $36 → $43 | Maintains | Outperform | Get Alert |
| 12/06/2023 | Buy Now | — | RBC Capital | Gregory Renza52% | $36 → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 11/30/2023 | Buy Now | — | JP Morgan | Anupam Rama59% | $35 → $41 | Maintains | Overweight | Get Alert |
| 11/13/2023 | Buy Now | — | Wedbush | Robert Driscoll44% | → $43 | Reiterates | Outperform → Outperform | Get Alert |
| 11/08/2023 | Buy Now | — | Guggenheim | Vanck Zhu75% | $48 → $44 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | — | Wedbush | Robert Driscoll44% | → $43 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2023 | Buy Now | — | RBC Capital | Gregory Renza52% | $32 → $36 | Maintains | Outperform | Get Alert |
| 10/11/2023 | Buy Now | — | RBC Capital | Gregory Renza52% | → $32 | Reiterates | Outperform → Outperform | Get Alert |
| 09/12/2023 | Buy Now | — | Wedbush | Robert Driscoll44% | $40 → $43 | Maintains | Outperform | Get Alert |
| 09/12/2023 | Buy Now | — | Goldman Sachs | Corinne Jenkins47% | $31 → $37 | Maintains | Buy | Get Alert |
| 08/17/2023 | Buy Now | — | JP Morgan | Anupam Rama59% | $28 → $32 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | — | RBC Capital | Gregory Renza52% | $30 → $32 | Maintains | Outperform | Get Alert |
| 08/11/2023 | Buy Now | — | Wedbush | Robert Driscoll44% | $35 → $40 | Maintains | Outperform | Get Alert |
| 08/11/2023 | Buy Now | — | Oppenheimer | Matthew Biegler40% | $30 → $35 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | — | SVB Leerink | Christopher Liu50% | → $33 | Initiates | → Outperform | Get Alert |
| 05/24/2023 | Buy Now | — | Goldman Sachs | Corinne Jenkins47% | → $32 | Initiates | → Buy | Get Alert |
| 04/24/2023 | Buy Now | — | Guggenheim | Vanck Zhu75% | $32 → $40 | Maintains | Buy | Get Alert |
| 04/24/2023 | Buy Now | — | Stifel | Benjamin Burnett44% | $18 → $24 | Upgrade | Hold → Buy | Get Alert |
| 03/23/2023 | Buy Now | — | Berenberg | Zhiqiang Shu21% | → $26 | Initiates | → Buy | Get Alert |
| 03/08/2023 | Buy Now | — | Guggenheim | Charles Zhu65% | → $32 | Reiterates | → Buy | Get Alert |
| 03/08/2023 | Buy Now | — | RBC Capital | Gregory Renza52% | → $25 | Reiterates | → Outperform | Get Alert |
| 02/28/2023 | Buy Now | — | RBC Capital | Gregory Renza52% | → $25 | Initiates | → Outperform | Get Alert |
| 12/28/2022 | Buy Now | — | Capital One | Zegbeh Jallah66% | → $29 | Initiates | → Overweight | Get Alert |
| 11/18/2022 | Buy Now | — | Baird | Joel Beatty68% | $18 → $24 | Maintains | Outperform | Get Alert |
| 10/27/2022 | Buy Now | — | Citigroup | Yigal Nochomovitz53% | → $26 | Initiates | → Buy | Get Alert |
| 09/13/2022 | Buy Now | — | Guggenheim | Charles Zhu65% | $20 → $32 | Maintains | Buy | Get Alert |
| 08/16/2022 | Buy Now | — | Baird | Joel Beatty68% | $26 → $18 | Maintains | Outperform | Get Alert |
| 08/16/2022 | Buy Now | — | Oppenheimer | Matthew Biegler40% | $25 → $20 | Maintains | Outperform | Get Alert |
| 08/15/2022 | Buy Now | — | Stifel | Benjamin Burnett44% | $16 → $13 | Downgrade | Buy → Hold | Get Alert |
FAQ
What is the target price for IDEAYA Biosciences (IDYA) stock?
The latest price target for IDEAYA Biosciences (NASDAQ:IDYA) was reported by Wells Fargo on June 26, 2025. The analyst firm set a price target for $44.00 expecting IDYA to rise to within 12 months (a possible 94.78% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for IDEAYA Biosciences (IDYA)?
The latest analyst rating for IDEAYA Biosciences (NASDAQ:IDYA) was provided by Wells Fargo, and IDEAYA Biosciences initiated their overweight rating.
When was the last upgrade for IDEAYA Biosciences (IDYA)?
The last upgrade for IDEAYA Biosciences Inc happened on April 24, 2023 when Stifel raised their price target to $24. Stifel previously had a hold for IDEAYA Biosciences Inc.
When was the last downgrade for IDEAYA Biosciences (IDYA)?
The last downgrade for IDEAYA Biosciences Inc happened on November 5, 2024 when Leerink Partners changed their price target from $41 to $27 for IDEAYA Biosciences Inc.
When is the next analyst rating going to be posted or updated for IDEAYA Biosciences (IDYA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IDEAYA Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IDEAYA Biosciences was filed on June 26, 2025 so you should expect the next rating to be made available sometime around June 26, 2026.
Is the Analyst Rating IDEAYA Biosciences (IDYA) correct?
While ratings are subjective and will change, the latest IDEAYA Biosciences (IDYA) rating was a initiated with a price target of $0.00 to $44.00. The current price IDEAYA Biosciences (IDYA) is trading at is $22.59, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
